Abstract | PURPOSE: METHODS: PK/PD modeling was applied to explore the relationship between siltuximab PK and CRP suppression following intravenous siltuximab infusion in 47 patients with B cell non-Hodgkin's lymphoma (n = 17), multiple myeloma (n = 13), or CD (n = 17). Siltuximab was administered as 2.8, 5.5, or 11 mg/kg q2wks, 11 mg/kg q3wks, or 5.5 mg/kg weekly. Simulations of studied or hypothetical siltuximab dosage regimens (15 mg/kg q4wks) were also performed to evaluate maintenance of CRP suppression below the cutoff value of 1 mg/L. RESULTS: A two-compartment PK model and an inhibitory indirect response PD model adequately described the serum siltuximab and CRP concentration-time profiles simultaneously. PD parameter estimates were physiologically plausible. For all disease types, simulations showed that 11 mg/kg q3wks or 15 mg/kg q4wks would reduce serum CRP to below 1 mg/L after the second dose and throughout the treatment period. CONCLUSIONS: PK/PD modeling was used to select doses for further development of siltuximab in multicentric CD. The dosing recommendation was also supported by the observed efficacy dose-response relationship. CRP suppression in the subsequent randomized multicentric CD study was in agreement with the modeling predictions.
|
Authors | Christina L Mayer, Lanyi Xie, Rajesh Bandekar, Ming Qi, Helgi van de Velde, Manjula Reddy, Xiang Qin, Hugh M Davis, Thomas A Puchalski |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 75
Issue 5
Pg. 1037-45
(May 2015)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 25784388
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- siltuximab
|
Topics |
- Aged
- Antibodies, Monoclonal
(administration & dosage, blood, pharmacokinetics)
- Antineoplastic Agents
(administration & dosage, blood, pharmacokinetics)
- Castleman Disease
(blood, drug therapy, metabolism)
- Dose-Response Relationship, Drug
- Humans
- Infusions, Intravenous
- Middle Aged
- Models, Biological
- Randomized Controlled Trials as Topic
|